Stock Analiz

Clene Inc. CLNN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.92Market cap $56M
Open the interactive analysis →

Clene Inc. (CLNN) is a healthcare company listed in the US with a market value of about $56M. In the twelve months to September 30, 2026 it had revenue of $238000 and net income of -$27M, a net margin of -11271.4%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -1% a year, a 5-year average ROIC of -588%.

About Clene

Clene is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $206000 in 2020 to $200000 in 2025, a decline of about 0.6% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 202% over three years (dilution for shareholders). It spends 7006% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S237.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-29.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-41.5%
Revenue growth (5 yrs, per year)-0.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-7969.7%
ROIC (5-yr avg.)-588.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$238000$200000$342000$654000$473000$723000$206000—
Net income-$27M-$26M-$39M-$50M-$30M-$10M-$19M-$16M
Free cash flow-$17M-$19M-$21M-$31M-$44M-$36M-$19M-$13M
EPS (diluted)$-2.35$-2.65$-5.67$-9.43$-9.20$-3.20$-22.00$-18.60
Net margin-11271.4%-13086.5%-11520.5%-7569.4%-6325.2%-1347.2%-9357.8%—
ROIC—-542.9%-1945.5%-113.3%-187.8%-150.6%-156.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Clene pay a dividend?

Not currently.

Is Clene a good stock to buy?

We do not give buy or sell advice. Clene scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.